Related Experiment Video
Updated: Sep 4, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
Reduction in Postprandial Peak Glucose With Increased Technosphere Insulin Dosage
Kevin B Kaiserman1, Mark Christiansen2, Sunil Bhavsar1
1MannKind Corporation, Westlake Village, CA, USA.
Journal of Diabetes Science and Technology
|July 14, 2022
Summary
A higher dose of Technosphere Insulin (TI), an inhaled insulin, significantly reduced postprandial glucose excursions compared to the standard dose. This enhanced dosing strategy showed no new safety concerns, potentially improving glucose control.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Technosphere Insulin (TI) is an ultra-rapid-acting inhaled insulin.
- Current dosing guidelines for TI may not fully optimize postprandial glucose control.
Purpose of the Study:
- To compare the efficacy of a higher TI dose (dose 2) versus the standard label dose (dose 1) in reducing postprandial glucose excursion (PPGE).
- To evaluate safety, including hypoglycemia and pulmonary function (FEV1), with both TI doses.
Main Methods:
- Twenty patients with diabetes on basal-bolus insulin therapy participated.
- Each patient received both dose 1 and dose 2 of TI in a crossover design before an identical meal.
- Postprandial glucose levels and FEV1 were monitored for two hours.
Main Results:
- Dose 2 significantly reduced mean PPGE from 45 to 120 minutes post-meal (P < .0001).
- Mean peak glucose at two hours decreased from 228.6 to 179.3 mg/dL (P < .001) with dose 2.
- Two mild hypoglycemic events occurred in one subject with dose 2; no significant changes in FEV1 were observed.
Conclusions:
- A higher TI dose effectively reduces immediate postprandial hyperglycemia compared to the standard dose.
- This higher dosing strategy appears safe and may offer improved prandial glucose management when confirmed in larger trials.
More Related Videos
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.2K
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
69.2K
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
246
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
246
01:23Dipeptidyl Peptidase 4 Inhibitors
246
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
246
01:06Oral Hypoglycemic Agents: Glinides
250
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
250
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
281
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
281
01:24Glucagon-like Receptor Agonists
409
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
409
01:16Hormones Regulating Blood Glucose
3.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.9K